Internal Medicine, Hematology & Oncology · Beverly Hills, CA
NPI
1366698912
Since 2008
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
8900 Wilshire Blvd Ste 200
Beverly Hills, CA, 90211
Phone (310) 432-8900
Groups this clinician bills Medicare through
Medicare paid, 2024
$923K
41,413 services
Medicare patients, 2024
303
Average age 72
Drug cost, 2024
$4.9M
1,153 prescriptions
Company payments, 2025
$5,295
From 45 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Howard S Yeh was code J2405 (injection, ondansetron hydrochloride, per 1 mg), 1,960 times for 32 patients. In total Howard S Yeh billed 41,413 services in 100 codes, and Medicare paid $923K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-09-23.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 1,960 | 32 | $0.07 | $143 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,445 | 32 | $0.09 | $126 |
| 99214 Office E&M - Established | Office | 553 | 190 | $97.91 | $54K |
| 96413 Chemotherapy Administration | Office | 213 | 44 | $116.49 | $25K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 186 | 98 | $13.63 | $2,536 |
| M0010 Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 169 | 34 | $91.56 | $15K |
| 96367 Intravenous Infusion, Hydration | Office | 155 | 38 | $25.04 | $3,881 |
| 99442 Telephone Services | Office | 116 | 45 | $47.10 | $5,463 |
| J1200 Injection, diphenhydramine hcl, up to 50 mg | Office | 97 | 28 | $0.62 | $60.57 |
| 96417 Chemotherapy Administration | Office | 90 | 21 | $58.57 | $5,271 |
| 99213 Office E&M - Established | Office | 60 | 47 | $59.66 | $3,579 |
| 96372 Injection Administration | Office | 59 | 14 | $11.97 | $706 |
| 36591 Vascular | Office | 56 | 14 | $24.36 | $1,364 |
| 96415 Chemotherapy Administration | Office | 55 | 21 | $25.33 | $1,393 |
| J7040 Infusion, normal saline solution, sterile (500 ml = 1 unit) | Office | 52 | 11 | $0.99 | $51.35 |
By year: 2022 $174K for 7,460 services; 2023 $573K for 20,823 services; 2024 $923K for 41,413 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 22 | 20 | $8.65 | $190 |
Medicare prescription drug claims, 2024
In 2024, the drug Howard S Yeh prescribed most often to Medicare patients was Letrozole, with 146 prescriptions and refills. In total Howard S Yeh wrote 1,153 Medicare prescriptions that cost $4.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Letrozole Generic | 146 | 271 | 50 | $2,554 |
| Keytruda Pembrolizumab | 49 | 49 | Under 11 | $505K |
| Tagrisso Osimertinib Mesylate | 37 | 37 | Under 11 | $615K |
| Xtandi Enzalutamide | 34 | 34 | Under 11 | $449K |
| Alendronate Sodium Generic | 34 | 58 | 15 | $232 |
| Ondansetron Hcl Ondansetron Hcl/Pf | 34 | 34 | Under 11 | $99.62 |
| Anastrozole Generic | 32 | 80 | 16 | $683 |
| Dexamethasone Sodium Phosphate Generic | 32 | 32 | Under 11 | $55.31 |
| Verzenio Abemaciclib | 30 | 30 | Under 11 | $451K |
| Prednisone Generic | 27 | 30 | Under 11 | $87.91 |
| Imatinib Mesylate Generic | 25 | 25 | Under 11 | $26K |
| Zoledronic Acid Generic | 24 | 47 | Under 11 | $1,058 |
| Carboplatin Generic | 24 | 24 | Under 11 | $899 |
| Diphenhydramine Hcl Generic | 22 | 22 | Under 11 | $40.61 |
| Dexamethasone Generic | 22 | 30 | Under 11 | $242 |
Brand drugs: 421 claims; generic drugs: 732 claims; opioid claims: 18.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Howard S Yeh $5,295 ($5,295 in general payments such as food, travel and fees) from 45 companies. The largest payer was Daiichi Sankyo Inc. with $771.
| Company | Payments | Amount |
|---|---|---|
| Daiichi Sankyo Inc. 4568.T | 11 | $771 |
| AstraZeneca Pharmaceuticals LP AZN | 29 | $711 |
| Janssen Biotech, Inc. JNJ | 15 | $370 |
| Novartis Pharmaceuticals Corporation NVS | 12 | $273 |
| Astellas Pharma US Inc 4503.T | 15 | $267 |
| Merck Sharp & Dohme LLC MRK | 11 | $255 |
| Pfizer Inc. PFE | 18 | $225 |
| Stemline Therapeutics Inc. | 8 | $216 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 8 | $206 |
| Abbvie Inc. ABBV | 10 | $198 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.